Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Health CanadaRegulator guidanceLot release and sample testingBiologicsHigh confidenceLast verified October 5, 2026

HC Lot Release Program guidance

Guidance on the Lot Release Program for Schedule D (biologic) drugs

Current edition

Published April 15, 2026

About this standard

Describes the risk-based Lot Release Program in which each lot of a biologic drug is reviewed, and in some groups tested, before sale in Canada.

Recognition by market

Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts

No market listing is published yet.

Testing requirements that cite it

Open the market page and its pathway pages for the full requirement, protocol and report content

Canada

Related standards: MHRA Responsible Person (import) guidance, EudraLex Volume 4 Annex 16, TGA vaccine batch release, MFDS imported drug management regulation, MFDS national lot release regulation, RDC 669/2022, RDC 670/2022, RDC 900/2024, RDC 944/2024, SFDA lot release policy, Taiwan biological product lot release regulations. See all standards.

Not legal or regulatory advice. Check the current official rules before you act. Parts of the approvals data are official open data reused under open licences. Data sources.

LinkedInLinkedInXXYouTubeYouTube